Seth Lederman - Feb 5, 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role: Chief Executive Officer, Director
Signature: /s/ Seth Lederman
Stock symbol: TNXP
Transactions as of: Feb 5, 2025
Transactions value $: -$18
Form type: 4
Date filed: 2/27/2025, 06:48 PM
Previous filing: Feb 29, 2024
Next filing: May 15, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNXP	Common Stock, $0.001 par value	Other	-$18	-5.18	-50.88%	$3.38	5	Feb 5, 2025	Direct	F2
transaction	TNXP	Common Stock, $0.001 par value	Other	-$1	-0.22	-18.03%	$3.30	1	Feb 5, 2025	By IRA Account	F2
transaction	TNXP	Common Stock, $0.001 par value	Other	$0	-1	-100%	$0.15	0	Feb 5, 2025	By Spouse	F2
holding	TNXP	Common Stock, $0.001 par value						5	Feb 5, 2025	Direct
holding	TNXP	Common Stock, $0.001 par value						1	Feb 5, 2025	By IRA Account
holding	TNXP	Common Stock, $0.001 par value						1	Feb 5, 2025	Lederman & Co.	F1

Showing 1 to 6 of 6 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNXP	Stock Option	Award	$0	+124K		$0.00	124K	Feb 25, 2025	Common Stock	124K	$8.05	Direct	F3, F4
transaction	TNXP	Stock Option	Award	$0	+124K		$0.00	124K	Feb 25, 2025	Common Stock	124K	$10.06	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reporting person may be deemed to be a control person of this entity.
F2	Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock.
F3	One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F4	The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.